The ®broblast growth factor-binding protein (FGF-BP) modulates FGF activity through binding and release from the extracellular matrix. Consequently, the expression of FGF-BP in certain tumor types is a rate-limiting regulator of FGF-mediated angiogenesis. FGF-BP is upregulated in squamous cell carcinoma by treatment with mitogens such as EGF or TPA. In this study, we investigated the regulation of FGF-BP gene expression by serum. Treatment of serum-starved ME-180 cells with fetal bovine serum (FBS) resulted in a rapid increase in steady-state levels of FGF-BP mRNA and in the rate of FGF-BP gene transcription. Serum induction of FGF-BP mRNA was not mediated through EGF receptor activation but was dependent on PKC, as well as ERK kinase (MEK) and p38 MAP kinase activation. Promoter analysis showed that C/EBP is the main promoter element required for the serum response. Unlike EGF-activation of FGF-BP, transcriptional induction by serum is not signi®cantly regulated through the AP-1 or E-box sites in the promoter. These results illustrate dierences between the mechanism of induction in response to serum and EGF. Oncogene (2001) 20, 1730 ± 1738.
Introduction
The ®broblast growth factor-binding protein (FGF-BP) is a secreted protein which binds and releases FGF-1 and FGF-2 stored in the extracellular matrix (Czubayko et al., 1994; Wu et al., 1991) . The noncovalent binding between FGF-BP and FGFs protects the released FGF from degradation and allows it to reach its target receptor (Czubayko et al., 1994) , thereby activating FGF-mediated processes such as growth, dierentiation, and angiogenesis. Whereas FGF-1 and FGF-2 are abundantly expressed in most tissues, FGF-BP expression is limited to embryonic skin, intestine, and lung and is low in most adult tissues (Kurtz et al., 1997) , thus providing a tissue-speci®c mechanism for the activation of stored FGF. Studies have shown that the ectopic expression of FGF-BP can induce tumorigenicity and stimulate angiogenesis in an adrenal carcinoma cell line (Czubayko et al., 1994) . More recently, it was discovered that FGF-BP is highly expressed in squamous cell carcinoma (SCC) cell lines and tumor tissues (Czubayko et al., 1994; Kurtz et al., 1997) . Depletion of endogenous FGF-BP in the cervical SCC cell line ME-180 using ribozyme targeting signi®cantly impairs the tumorigenic and angiogenic phenotype by inhibiting the release of matrix-stored FGF-2 (Czubayko et al., 1997) . In addition to SCC, FGF-BP was also found to be expressed in some colon carcinomas, and ribozyme-mediated reduction of FGF-BP levels in colon cancer cell lines played a signi®cant role in their ability to form xenotransplanted tumors (Czubayko et al., 1997) . Therefore, for some tumor types including SCC and colon carcinoma, FGF-BP expression can play a rate-limiting role in tumor growth and angiogenesis.
Because FGF-BP expression is aberrantly expressed in some tumors where it seems to play a functional role in the activation of FGFs during tumorigenesis, it is necessary to understand the mechanisms by which FGF-BP gene expression is regulated. The expression of FGF-BP has been shown to increase during DMBA/ TPA-induced mouse skin carcinogenesis (Kurtz et al., 1997) and is transcriptionally upregulated by TPA or EGF in SCC cell lines (Harris et al., 2000a (Harris et al., , 1998 . The rapid EGF induction of FGF-BP is dependent on two MAP kinase pathways; the MEK/ERK pathway and the stress-activated p38 pathway, which converge onto the AP-1, C/EBP, and E-box sites of the FGF-BP promoter to regulate transcription (Harris et al., 2000a,b) . The transcriptional induction by EGF or TPA is a rapid event, suggesting that FGF-BP is an immediate early gene target of mitogen stimulation.
In the present study, we investigated the response of the FGF-BP gene to serum stimulation. Serum contains a mixture of growth factors, cytokines, LPA, etc. and is an important source of mitogens for cultured cells as well as for tissues during processes such as wound healing. The proliferative response to serum has been studied extensively and is characterized by the rapid activation of MAP kinase pathways and the induction of immediate early genes, many of which encode members of the AP-1 transcription factor family (c-fos and c-jun) (Herschman, 1991; Iyer et al., 1999) . We found that serum stimulation of SCC cells causes a rapid increase in FGF-BP gene transcription and we have characterized this response with respect to the mechanisms of signal transduction.
Results

Serum induction of FGF-BP gene expression through a rapid increase in rate of transcription
The induction of FGF-BP by mitogens such as EGF and TPA has been studied previously and was shown to occur through distinct signal transduction and transcriptional mechanisms (Harris et al., 1998; 2000a) . In order to understand how FGF-BP might be regulated by a physiological source of mitogens, we tested whether fetal bovine serum (FBS) could also regulate FGF-BP expression. As a model, we used the human cervical SCC cell line ME-180, which expresses high amounts of FGF-BP and is dependent on the level of FGF-BP expression for tumor formation (Czubayko et al., 1997) . As shown in Figure 1 , treatment of serum-starved ME-180 cells with 10% FBS resulted in a rapid and transient increase in FGF-BP mRNA which peaked after 6 h. This time course of serum induction was very similar to EGF (Figure 1 ) and TPA (Harris et al., 1998) induction of FGF-BP in this cell line.
The rapid (within 1 h) induction of FGF-BP mRNA by serum suggested a direct transcriptional mechanism. To examine the eect of serum on the rate of transcription of FGF-BP, we conducted nuclear runon analysis in ME-180 cells which were either untreated (serum-free) or treated for 1 h with 10% FBS. Quantitation of hybridized nascent RNA transcript (Figure 2 , upper panel) revealed a fourfold increase in the rate of FGF-BP transcription after serum treatment (lower panel). In support of a direct transcriptional mechanism, we found that treatment with the transcriptional inhibitor actinomycin D completely blocked serum induction of FGF-BP (Figure 3 ). In contrast, inhibition of protein synthesis with cycloheximide did not block the serum eect ( Figure 3 ) demonstrating that de novo protein synthesis is not required. Therefore, increased FGF-BP expression is a direct transcriptional eect of serum-induced signaling and displays characteristics of an immediate early, serum-responsive gene (Herschman, 1991 ).
Serum effect not mediated through EGF receptor pathway
Because both EGF and serum treatment increased FGF-BP mRNA with similar kinetics, we tested whether the serum eect was dependent on activation of the EGF receptor (EGFR) using the EGFR tyrosine kinase inhibitor AG1478. AG1478 had no eect on either basal or serum-induced levels of FGF-BP mRNA (Figure 4 ), but completely blocked EGF induction (Figure 4, and Harris et al., 2000a) . Blocking antibodies for the EGFR were also unable to inhibit the serum response (data not shown). In addition, there was no inhibition of serum induction using inhibitors of the PDGF receptor tyrosine kinase (AG1296) and we found no eect on FGF-BP gene expression with other growth factors such as PDGF-BB or IGF-I (data not shown). Taken together, these data demonstrate that activation of the EGFR is not necessary for the serum eect, suggesting that serum induction of FGF-BP is mediated through an alternate receptor pathway(s).
Serum induction is dependent on activation of PKC, MEK, and p38 MAP kinase
We next investigated which signal transduction pathways are involved in the serum regulation of FGF-BP. We reported previously that TPA and EGF both require PKC activation for their eects on FGF-BP since induction was blocked in the presence of the PKC inhibitor calphostin C (Harris et al., 1998; 2000a) . Similarly, Figure 5a shows that serum induction of We also investigated which signaling pathways downstream of PKC might contribute to the serum induction of FGF-BP mRNA. In particular, MAP kinase pathways including ERK1/2, p38 and JNK are often activated in response to mitogenic stimuli (English et al., 1999) and can cooperate to activate gene expression in response to serum (Whitmarsh et al., 1995) . We therefore tested the eect of pharmacological inhibition of MEK, the upstream kinase activator of ERK, on the serum regulation of FGF-BP. Pretreatment with the drug U0126 (a MEK1/2 inhibitor) signi®cantly blocked both serum ( Figure 5a ) and EGF (Figure 5b ) induction of FGF-BP mRNA. The involvement of MEK and ERK in FGF-BP regulation has also been shown through expression of dominant-negative forms of MEK2 or ERK2 (Harris et al., 2000a) . Therefore, the serum regulation of FGF-BP is mediated at least in part through MEK/ERK activation.
In earlier studies, FGF-BP promoter activity was found to be signi®cantly increased upon overexpression of p38 MAPK and MKK6 (an upstream kinase that is speci®c for p38 MAPK), but not by overexpression of JNK (Harris et al., 2000a) . To test whether p38 activation was required for serum induction of FGF-BP we utilized a speci®c p38 inhibitor (SB202190) which has no eect on JNK or ERK kinase activity (Cuenda et al., 1995; Kumar et al., 1997) . Treatment with SB202190 signi®cantly blocked both serum ( Figure 5a ) and EGF ( Figure 5b ) induction to the level of the untreated control. In contrast, treatment with SB202474, a drug that has a similar structure but is unable to inhibit p38, had no eect on either serum (Figure 5a ) or EGF (Harris et al., 2000a) induction of FGF-BP. These results show that p38 MAPK, in addition to MEK/ERK, is also required for serum regulation of the FGF-BP gene.
The activation of PI 3-kinase is another important signal transduction pathway known to contribute to tumor progression through cell cycle stimulation and protection from apoptosis (Kandel and Hay, 1999). With regard to FGF-BP, however, we found that PI 3-kinase does not play a role in the EGF regulation of FGF-BP (Harris et al., 2000a) . To examine whether the PI 3-kinase is perhaps involved in the serum response, we treated with the drug wortmannin, which has been shown to inhibit Akt kinase activity (downstream target of PI 3-kinase) in ME-180 cells (Harris et al., 2000a) . Wortmannin treatment did not signi®cantly inhibit serum induction of FGF-BP mRNA ( Figure  5a ), indicating that the PI 3-kinase/Akt pathway does not play a major role in the serum regulation of this gene.
Serum response mediated through the C/EBP site in the FGF-BP promoter
The human FGF-BP gene promoter was cloned previously (Harris et al., 1998) , and regulation of promoter activity in SCC cells was found to be mediated through the ®rst 118 base pairs of the proximal promoter sequence (Harris et al., 1998 (Harris et al., , 2000a . Important regulatory elements within this region are depicted in Figure 6a and include two Sp1 binding sites (Sp1(a) and Sp1(b)), AP-1, E-box, and C/ EBP binding sites. We examined which of these promoter elements were involved in the serum regulation of FGF-BP using a series of promoter constructs containing deletions or mutations in the above mentioned regulatory elements. Each construct was transiently transfected into ME-180 cells and the fold induction of each construct in response to 10% FBS treatment was determined. As shown in Figure 6b , full serum induction was maintained when the a b Figure 5 Eect of signal transduction inhibitors on serum induction of FGF-BP mRNA. ME-180 cells were pretreated in serum-free conditions for 1 h in the absence or presence of 100 nM calphostin C (PKC inhibitor), 1 mM wortmannin (PI3 kinase inhibitor), 20 mM U0126 (MEK1/2 inhibitor), 20 mM SB202190 (p38 inhibitor), or 20 mM SB202474 (p38 inhibitor control. Pretreatment was followed by 6 h stimulation with 10% FBS (a) or 5 ng/ml EGF (b). Northern blot signal intensities of FGF-BP mRNA were quantitated, normalized to GAPDH, and expressed as per cent of FBS-treated control (no drug), (a), or relative to untreated control, (b). Values represent mean and standard error for at least three separate determinations. Asterisk in (a) indicates signi®cant dierence (P50.01, Student's t-test) compared to the FBS-treated control Figure 4 Eect of EGF receptor inhibition on serum and EGF induction of FGF-BP. ME-180 cells were pretreated in serum-free conditions for 1 h in the absence or presence of the EGFR tyrosine kinase inhibitor AG1478 (100 mM), followed by no treatment or treatment for 6 h with 10% FBS or 5 ng/ml EGF. Northern blot signal intensities of FGF-BP mRNA were quantitated, normalized to GAPDH, and expressed relative to untreated control. Values represent mean and standard error for at least three separate determinations. Asterisks indicate signi®cant dierence (P50.01, Student's t-test) compared to either the untreated control (*), or the EGF-treated control (**) promoter was deleted from 71060 to 7118, demonstrating that like TPA and EGF, the serum eect on FGF-BP transcription is mediated through this important regulatory region. These values corresponded to an average serum induction of approximately 3.5-fold (data not shown). Deletion of either the Sp1(a) site (data not shown) or Sp1(b) site (Figure 6b ) had no signi®cant eect on serum induction, although these deletions resulted in a signi®cant drop in the overall basal promoter activity (Harris et al., 1998) . Interestingly, mutation of the AP-1 site (mutAP-1) decreased serum induction of the promoter only by an average of 25%, which was not signi®cantly dierent when compared to the fold induction of the 7118/+62 construct (Figure 6b ). This is in contrast to EGF regulation of the promoter, which was signi®cantly decreased by 40% upon AP-1 site mutation (Harris et al., 2000a ). These results demonstrate dierences in the mechanism of FGF-BP transcriptional regulation by serum (AP-1-independent) and EGF (AP-1-dependent).
To test the contribution of the C/EBP element to serum induction, we transfected a promoter construct harboring an internal deletion of the C/EBP site (DC/ EBP). Loss of an intact C/EBP element signi®cantly reduced the serum eect by 60% (Figure 6b) , with no alteration in basal promoter activity (Harris et al., 1998) . The requirement for an intact C/EBP element in serum-induced FGF-BP transcription is similar to that seen for both EGF (Harris et al., 2000a) and TPA (Harris et al., 1998) Figure  6b ). Deletion of AP-1 along with C/EBP did not result in any added inhibition of promoter activity, supporting the observation that serum induction is not dependent on the AP-1 site. These results demonstrate that serum induction of FGF-BP is predominantly dependent on the C/EBP promoter element for full transcriptional induction, in contrast to EGF induction, which depends on both C/EBP and AP-1.
In addition to these positive regulatory elements, FGF-BP is also regulated by an E-box site, which functions to repress TPA or EGF-induced transcription (Harris et al., 2000b) . Point mutation of the E-box site at position 758 substantially increases the overall fold induction by TPA or EGF and inhibits the binding of USF in vitro (Harris et al., 2000b) . In contrast, mutation of the E-box had no signi®cant eect on serum induction of the FGF-BP promoter (Figure 6b , mut-58), which consistently showed the same level of serum induction as the 7118 promoter construct. This result illustrates an important distinction in signal-induced regulation of the FGF-BP promoter, indicating that subtle dierences in the serum-induced ERK and p38 MAPK pathways result in high levels of FGF-BP gene expression without utilizing AP-1 or E-box factors (USF/c-Myc).
Serum induces the binding of a C/EBP complex to the FGF-BP promoter
Because the C/EBP site on the FGF-BP promoter seems to be important during serum and EGF (b) ME-180 cells were transiently transfected with the indicated FGF-BP promoter luciferase constructs and were treated for 18 h in IMEM alone or in IMEM+10% FBS. Promoter constructs are described in text and in Harris et al. (1998 Harris et al. ( , 2000a and all deletions or mutations were generated in the context of the 7118/ +62 promoter sequence. The D(776/756)/D(747/731) construct contains deletions of both the C/EBP and AP-1 sites. Luciferase activity was expressed as fold induction of treated over untreated for each construct and is shown as percentage of the fold induction of the 7118/+62 construct. Basal activity for each construct in ME-180 cells is shown elsewhere (Harris et al., 1998) . Values represent the mean and standard error from at least three experiments, each done in triplicate wells. Asterisk (*) indicates signi®cant dierence (P50.01, Student's t-test) compared to the 7118/+62 fold induction. Values for the DC/EBP and D(776/ 756)/D(747/731) constructs were not signi®cantly dierent from each other regulation of FGF-BP, we characterized the activity of C/EBP at the level of promoter binding to the C/EBP site on the FGF-BP promoter. In response to EGF, C/ EBPb and d are known to be the major components binding to the FGF-BP promoter (Harris et al., 2000a) . To compare C/EBP binding after EGF or serum treatment, we carried out gel shift analysis using labeled promoter sequence fragment from 755 to 730 (Figure 7a) , which was incubated in the presence of nuclear extracts from untreated, EGF, or serum treated ME-180 cells. In accordance to what we have shown previously, there were no qualitative or quantitative dierences in C/EBP complex formation between untreated and EGF treated ME-180 cells (Harris et al., 2000a, and Figure 7b, lanes 1 and 2) . In contrast, incubation with nuclear extract from serum treated cells, resulted in the formation of an upper complex not seen in either untreated or EGF treated extracts (lane 3, arrow). To determine if this complex does bind to C/EBP family members, we used an antibody for C/EBPb, that also cross-reacts with other C/EBP family members, for supershift analysis. Incubation with this antibody resulted in one supershifted band, and the disappearance of the induced complex (lane 4, asterisk). Furthermore, the addition of excess unlabeled consensus C/EBP elements eectively competed for binding to the serum-induced complex (lane 5). Thus, serum treatment results in formation of a unique C/EBP-containing complex, which is not present after EGF treatment.
Because we previously observed AP-1 binding to the FGF-BP promoter is strongly induced after EGF treatment (Harris et al., 2000a) , we tested whether AP-1 factors also bind to the promoter in response to serum. Gel shift analysis was carried out using labeled promoter sequence fragment from 770 to 750 (Figure 7a ), and nuclear extracts from untreated or serum treated ME-180 cells. Protein binding in the uppermost complex, previously shown to represent AP-1 (Harris et al., 1998 (Harris et al., , 2000a , is induced by serum treatment (Figure 7c , lanes 1 and 2, arrow). Incubation with antibodies for Fos family members resulted in a supershifted complex (lane 3). Likewise, incubation with a general Jun family antibody blocked the formation of the AP-1 complex (lane 4, asterisk). These results demonstrate that serum induces the formation of a complex that binds Fos/Jun proteins on the FGF-BP promoter. Although we demonstrate AP-1 binding, this event does not appear to be rate limiting in the serum induction of FGF-BP transcription.
Induction of FGF-BP by serum and EGF is not additive
Based on the dierent yet overlapping sets of transcription factors involved in EGF versus serum regulation of FGF-BP, we hypothesized that activation of these pathways together may have an additive or synergistic eect on gene expression. ME-180 cells were treated with EGF and FBS, alone or in combination followed by analysis of FGF-BP mRNA levels. Figure 8 shows that each treatment alone caused maximal (fourfold) induction of FGF-BP mRNA. Combined treatment with FBS and EGF did not induce FGF-BP mRNA higher than fourfold. This result demonstrates that the EGF and serum-induced pathways are not additive and that each individual treatment is capable of achieving maximal induction of FGF-BP gene expression.
Discussion
We show here that the FGF-binding protein (FGF-BP) is regulated by serum (FBS) treatment through mechanisms involving ERK and p38 MAP kinases that ultimately activate FGF-BP transcription through the C/EBP element in the promoter region. Serum is a physiological source of growth factors which, when encountered by cells after wounding, helps mount a response involving cell proliferation, angiogenesis, in¯ammation, tissue remodeling, and re-epithelialization (Singer and Clark, 1999) . Serum treatment of ®broblasts rapidly induces an array of target genes (Iyer et al., 1999) , many of which are directly related to the wound healing response. Included in the panel of genes regulated by serum are a number of genes implicated in cancer progression, such as c-fos, c-myc, cyclin D1, VEGF, and FGF-2 (Iyer et al., 1999) . Indeed, many of the fundamental aspects of tumorigenesis (proliferation, angiogenesis, tissue remodeling) mimic processes that are essential for wound repair. The activation of FGF-BP by serum is signi®cant in this context since FGF-BP, which releases and activates FGF-2, has been implicated in tumor progression and angiogenesis of tumors (Czubayko et al., 1994 (Czubayko et al., , 1997 Kurtz et al., 1997) , as well as in tissue repair after wounding (unpublished results). From the present study, we conclude that FGF-BP is a direct target of serum that can contribute to angiogenesis in certain physiological situations such as cancer.
The transcriptional mechanism of FGF-BP gene regulation in response to serum diers signi®cantly from EGF regulation of this gene, which is surprising given that their kinetics and ecacy are very similar. The active component(s) in serum remains unknown at this point since neither EGFR nor PDGFR were required for the eect. Nevertheless, there is a mutual requirement for PKC, MEK/ERK and p38 MAP kinase activation in the upregulation of FGF-BP by both stimuli. In spite of these similarities, a dierential requirement for the AP-1 element in the FGF-BP promoter indicates a more subtle discrepancy between the two pathways that may be dicult to reveal with the use of pharmacological inhibitors. The selective AP-1 activation in response to EGF, for example, could be explained by eects on the duration of MAP kinase activation, either at the level of nuclear retention or inactivation by speci®c phosphatases (English et al., 1999) .
We have shown previously that the C/EBP, AP-1, and E-box promoter elements all play a role in regulating FGF-BP transcription in response to EGF (Harris et al., 2000a) . In the present study, we found through promoter analysis that in contrast to EGF stimulation, the majority of serum regulation of FGF-BP transcription depends on the C/EBP site. The dierence between EGF and serum stimulation is also re¯ected at the level of protein binding to the promoter, where we observed a serum-inducible C/ EBP complex, which was not present upon EGF stimulation (Figure 7b ). These ®ndings suggest that the unique C/EBP-containing complex induced by serum is most likely responsible for the dependence of serum induction on the C/EBP site. Several possibilities might account for the slower mobility of the serum-induced C/EBP complex. Stimulation with serum vs EGF might result in the recruitment of a dierent set of C/EBP binding partners, which can include other C/EBP family members, other leucine zipper factors, or transcriptional co-activators. Conversely, serum-induced phosphorylation of transcription factors that bind to the C/EBP site would also result in a slower mobility of the complex. For example, p38 MAPK has been shown to phosphorylate C/EBP family members, including C/EBPb (Engelman et al., 1998) and CHOP (Wang and Ron et al., 1996) , resulting in the increased transactivating ability and DNA-binding of these proteins. p38 MAPK can also phosphorylate other leucine zipper transcription factors such as ATF2 (Derijard et al., 1995; Raingeaud et al., 1995) and Elk-1 (Raingeaud et al., 1996) , which can bind as a heterodimer with C/EBP family members (Darlington et al., 1998; Diehl, 1998; Poli, 1998) .
Analysis of the FGF-BP promoter demonstrated only a minor role for AP-1 in the regulation of FGF-BP in response to serum, since mutation of the AP-1 element does not signi®cantly reduce the serum induction of promoter activity (Figure 6b ) despite the increase in AP-1 binding to the promoter. This observation is con®rmed by the lack of additional inhibition in the presence of a simultaneous C/EBP deletion, supporting the predominance of the C/EBP element alone in the serum regulation of this gene. In addition, we found no contribution of the E-box repressor element, which functions to limit transcriptional induction by TPA or EGF in an AP-1-dependent manner (Harris et al., 2000b) . Because neither the AP-1 mutation nor the m-58 E-box mutation had any signi®cant eect on serum induction, we conclude that the AP-1/E-Box composite regulatory element is not a major contributor of FGF-BP regulation in response to serum. Although the full impact of this dierence is not Figure 8 Eect of combined treatment with EGF and serum on FGF-BP mRNA induction. ME-180 cells were treated for 6 h with either IMEM alone, 10% FBS, 5 ng/ml EGF, or both FBS and EGF. Northern blot signal intensities of FGF-BP mRNA were quantitated, normalized to GAPDH, and expressed relative to untreated control. Values represent mean and standard deviation of two separate determinations evident in the overall kinetics of the response, we speculate that this may represent a signal-speci®c mechanism ensuring tight regulation of FGF-BP expression. Exploitation of the E-box repressor element in response to more eective signals, such as EGF, may re¯ect a pathway by which expression of this important angiogenic activator is limited.
In conclusion, this study characterizes the signal transduction and transcriptional mechanisms that mediate serum induction of the FGF-BP gene. A thorough understanding of the extracellular signals controlling the expression of FGF-BP is important, given that deregulated FGF-BP expression correlates signi®cantly with early tumor progression (Kurtz et al., 1997) , and causes markedly increased tumor formation and angiogenesis in experimental tumor models (Czubayko et al., 1994) . In addition, serum represents the soluble environment during tissue damage, suggesting that bleeding could be the reason for the upregulation of FGF-BP after wounding (A Kurtz and A Wellstein, unpublished data). Overall, this study illustrates the mechanisms by which FGF-BP can be regulated, both physiologically and therapeutically, to aect FGF-2 release and subsequent angiogenesis and tumor growth.
Materials and methods
Cell culture and reagents
The ME-180 cervical squamous cell carcinoma cell line was obtained from American Type Culture Collection (ATCC; Rockville, MD, USA). Cells were cultured in improved minimum essential medium (IMEM) with 10% fetal bovine serum (Life Technologies, Inc.). Signal transduction inhibitors included Actinomycin D, cycloheximide, calphostin C, and U0126 (Sigma); wortmannin (Biomol); AG1478, AG1296, SB202190, and SB202474 (Alexis Corp.). All compounds were dissolved in Me 2 SO.
Northern analysis ME-180 cells were grown to 80% con¯uence in 10-cm dishes, washed twice, and then incubated for 16 h in serum-free IMEM prior to treatment. Cells were pretreated for 1 h with the indicated drug or with vehicle alone (Me 2 SO, ®nal concentration 0.1%). FBS (10%) or EGF (5 ng/ml) treatment was for 6 h unless otherwise indicated. Total RNA was isolated with RNA STAT-60 TM (Tel-Test Inc.) and Northern analysis carried out as previously described (Harris et al., 1998) . Hybridization probes were prepared by random-primed DNA labeling (Amersham) of puri®ed insert fragments from human FGF-BP (Czubayko et al., 1994) and human GAPDH (Clontech). Quantitation of mRNA levels was performed using a PhosphorImager (Molecular Dynamics).
Transient transfections and reporter gene assays
Human FGF-BP promoter fragments were cloned into the pXP1 promoterless luciferase reporter vector and have been described previously (Harris et al., 1998) . The 7118D(776/ 756)/D(747/731) Luc FGF-BP promoter construct, which deletes the AP-1 and C/EBP sites, was made using PCR mutagenesis as described previously (Harris et al., 1998) . For transfection, ME-180 cells were plated in 6-well plates at a density of 750 000 cells/well. pRL-CMV Renilla luciferase reporter vector (Promega) was included as a control for transfection eciency. For each transfection, 1.0 mg FGF-BP promoter-luciferase construct, 0.1 ng pRL-CMV, and 8 ml Lipofectamine (Gibco-BRL) were combined and added to cells for 3 h in serum free conditions as described previously (Harris et al., 1998) . Transfected cells were treated for 18 h with 10% FBS or with EGF (5 ng/ml) in IMEM before cell lysis in 150 ml passive lysis buer (Promega). Twenty microliters of extract was assayed for both ®re¯y and Renilla luciferase activity using Dual-Luciferase TM reporter assay system (Promega). Due to a small background induction (1.5-fold) of the pRL-CMV plasmid, all luciferase values were normalized for protein content (Harris et al., 1998) . There were no signi®cant dierences, however, in the transfection eciencies between plasmid constructs in untreated controls as determined by Renilla luciferase assay. Protein content of cell extracts was determined by Bradford assay (Bio-Rad).
In vitro transcription on isolated nuclei ME-180 cells were grown to 80% con¯uence on 150 mm tissue culture dishes. Cells were washed in serum-free IMEM and then treated 16 h later with 10% FBS in IMEM for 1 h. Nuclei isolation, transcription assay, and hybridization conditions were exactly as described previously (LiaudetCoopman and Wellstein, 1996) . Labeled RNAs (10 7 c.p.m.) were hybridized to nylon membranes onto which 3 mg of each vector DNA was immobilized. pRC/FGF-BP construct contains the human FGF-BP open reading frame (Czubayko et al., 1994) , and pRC/CMV and b-actin plasmids were used as background and internal controls, respectively.
Gel shift assays ME-180 cells were grown to 80% con¯uency on 150-mm dishes, serum starved in IMEM for 16 h, and treated with or without, 5 ng/ml EGF or 10% FBS, for 1 h. Nuclear extracts were prepared as described previously (Harris et al., 1998) . Binding reactions with the 770/751 probe were carried out as described previously with 5 mg of ME-180 nuclear extracts, binding buer (20 mM Tris pH 7.5, 60 mM KC1, 5% glycerol, 0.5 nM dithiothreitol, 2.0 mM EDTA), and 250 ng of poly(dI-dC). Binding reactin with the 755/730 probe was carried out with 5 mg of ME-180 nuclear extracts and 500 ng of poly(dI-dC). Supershift antibodies (2 mg) were added to the binding reaction for 10 min on ice before adding 20 fmol of labeled probe. Reactions were carried out 20 min at room temperature and analysed by 6% polyacrylamide gel electrophoresis. Supershift antibodies purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA) were the following: Fos-speci®c antibody c-Fos (K-25), Jun-speci®c antibody c-Jun/AP-1 (D), and C/EBP-speci®c antibody C/EBPb (D198). For oligonucleotide competition, a 50-fold molar excess of unlabeled double-stranded competitor was added to the binding reaction and incubated for 10 min on ice before addition of the labeled probe. Sequence of the C/EBP consensus fragment was 5'-TGCAGATTGCG-CAATCTGCA-3' (Santa Cruz Biotechnology).
